Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment
Author:
Affiliation:
1. Shanghai China
2. Houston Texas
Funder
The grant from Clinical Research Center, Shanghai Jiao Tong University School of Medicine
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15273/fullpdf
Reference49 articles.
1. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption;Megraud;Gut,2013
2. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report;Malfertheiner;Gut,2017
3. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection;Liu;Helicobacter,2018
4. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy;Chen;Am J Gastroenterol,2016
5. Helicobacter pylori therapy: a paradigm shift;Graham;Expert Rev Anti Infect Ther,2016
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for Helicobacter pylori eradication: A prospective trial in Beijing;Heliyon;2024-04
2. Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review;Helicobacter;2024-01
3. Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis;Clinics and Research in Hepatology and Gastroenterology;2023-12
4. Advances in the pharmacological and regulatory management of multidrug resistant Helicobacter pylori;Expert Review of Clinical Pharmacology;2023-11-16
5. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment forHelicobacter pyloriinfection: a protocol of a single-centre, single-blind, randomised clinical trial in China;BMJ Open;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3